These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 19000250)
1. Phase I dose escalation of single-agent vinblastine in dogs. Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of vinblastine for treatment of canine mast cell tumors. Rassnick KM; Bailey DB; Flory AB; Balkman CE; Kiselow MA; Intile JL; Autio K J Vet Intern Med; 2008; 22(6):1390-6. PubMed ID: 19000249 [TBL] [Abstract][Full Text] [Related]
3. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vickery KR; Wilson H; Vail DM; Thamm DH Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670 [TBL] [Abstract][Full Text] [Related]
4. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014). Lenz JA; Robat CS; Stein TJ J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593 [TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556 [TBL] [Abstract][Full Text] [Related]
6. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. Frimberger AE; Moore AS; Rassnick KM; Cotter SM; O'Sullivan JL; Quesenberry PJ J Vet Intern Med; 2006; 20(2):355-64. PubMed ID: 16594594 [TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of vinorelbine in tumor-bearing cats. Pierro JA; Mallett CL; Saba CF J Vet Intern Med; 2013; 27(4):943-8. PubMed ID: 23662626 [TBL] [Abstract][Full Text] [Related]
8. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765 [TBL] [Abstract][Full Text] [Related]
9. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031 [TBL] [Abstract][Full Text] [Related]
10. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma. Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399 [TBL] [Abstract][Full Text] [Related]
11. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. Poirier VJ; Burgess KE; Adams WM; Vail DM J Vet Intern Med; 2004; 18(4):536-9. PubMed ID: 15320594 [TBL] [Abstract][Full Text] [Related]
12. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs. Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945 [TBL] [Abstract][Full Text] [Related]
13. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Harding K; Bergman N; Smith A; Lindley S; Szivek A; Milner R; Brawner W; Lejeune A Vet Comp Oncol; 2018 Dec; 16(4):636-641. PubMed ID: 30117260 [TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Thamm DH; Turek MM; Vail DM J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715 [TBL] [Abstract][Full Text] [Related]
15. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476 [TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714 [TBL] [Abstract][Full Text] [Related]
17. Dosage escalation of intravenous cyclophosphamide in cats with cancer. Moore AS; Frimberger AE; Chan CM Vet J; 2018 Dec; 242():39-43. PubMed ID: 30503542 [TBL] [Abstract][Full Text] [Related]
18. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378 [TBL] [Abstract][Full Text] [Related]
19. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma. Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727 [TBL] [Abstract][Full Text] [Related]
20. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]